Education
About Us
Working with TipRanks
Follow Us
IXICO PLC (GB:IXI)
LSE:IXI
IXI Stock Chart & Stats
11.75 p
-0.75 p(-6.25%)
At close: 4:00 PM EST
11.75 p
-0.75 p(-6.25%)
Day’s Range― - ―
52-Week Range7.00 p - 15.00 p
Previous CloseN/A
Volume22.18K
Average Volume (3M)123.87K
Market Cap
£7.23M
Enterprise Value3.87M
Total Cash (Recent Filing)£3.54M
Total Debt (Recent Filing)£179.00K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,668,594
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.50M
Bulls Say, Bears Say
Bulls Say
Specialized Neuroimaging AnalyticsIXICO's focused business model in neuroimaging and biomarker analytics creates a durable competitive niche. Deep technical expertise and regulatory-aligned services support repeat contract demand from pharma/biotech, making revenue streams sticky and aligned with long-term CNS drug development trends.
Order Book Expansion And Revenue MomentumA materially larger order book and a reported 1.5 book-to-bill ratio provide multi-quarter revenue visibility and demonstrate durable client demand. This backlog supports management's 15% revenue guidance and reduces near-term sales risk while enabling operational scaling toward profitability thresholds.
Conservative Balance Sheet And Cash BufferLow leverage and a positive net asset position give IXICO financial flexibility to fund platform investment and take on longer trials without immediate refinancing. The cash buffer and conservative balance sheet reduce liquidity risk and support execution of strategic partnerships and R&D initiatives.
Bears Say
Ongoing Net LossesPersistent net losses and negative operating margins limit the company's ability to self-fund growth and increase dependency on external financing or dilution. Continued unprofitability constrains reinvestment capacity and raises execution risk before sustainable margin expansion is achieved.
Weak Cash GenerationNegative operating cash flow and volatile free cash flow indicate inefficiencies converting revenue into usable cash. This reduces runway, increases funding needs, and makes long-term investments or scaling initiatives contingent on successful working capital management or external capital.
Profitability Dependent On Revenue ThresholdManagement's breakeven point creates binary execution risk: failure to sustain the forecasted revenue trajectory delays profitability. Achieving that threshold requires continued order conversion, pricing stability and margin discipline; any slowdown materially extends the loss-making period.
IXICO plc News
IXI FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest share price was 7.00 p and its highest was 15.00 p in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is £7.23M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is May 26, 2026 which is in 70 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on Dec 09, 2025. The company reported -0.008 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.008 p.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 92,668,594 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -0.008 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.953%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in GB:IXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―